Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANDES
2025-520954-12-00Phase 4Authorised
- Sponsor
- CHU de Québec-Université Laval
- Start
- Feb 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised trial of dabigatran, apixaban, edoxaban, rivaroxaban, aspirin and 1 more in Atrial fibrillation (AFib) and thrombosis (2 arms), sponsored by CHU de Québec-Université Laval. Primary endpoints: Device thrombosis at 60 days by TEE and Adverse clinical events at 60 days. Planned start Feb 2025; status: authorised.
02
Drugs
dabigatranapixabanedoxabanrivaroxabanaspirin
03
Conditions
Atrial fibrillation (AFib)thrombosis
Beyond the preview
Go deeper on 2025-520954-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520954-12-00.